Protagonist Therapeutics
PTGX
38 hedge funds and large institutions have $175M invested in Protagonist Therapeutics in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 6 reducing their positions, and 4 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 6
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
47.74% more ownership
Funds ownership: 0% → 47.74% (+48%)
21% more capital invested
Capital invested by funds: $145M → $175M (+$30M)
12% more funds holding
Funds holding: 34 → 38 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.44M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.74M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$1.38M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$846K |
| 5 |
State Street
Boston,
Massachusetts
|
+$692K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$7.92M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.78M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.74M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.38M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.11M |
PTGX Hedge Fund Activity: Q4 2016 in Review
38 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q4 2016, worth a combined $175M — up 21% from $145M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new PTGX positions and 4 closed out — a net gain of 4 holders — while 21 added to existing stakes and 6 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $8.44M. The largest seller was BVF Inc, exiting entirely with an estimated $7.92M sold.
- 38 institutional investors held Protagonist Therapeutics (PTGX) as of Q4 2016, up from 34 in Q3 2016.
- Funds reported $175M of Protagonist Therapeutics stock for Q4 2016, up 21% quarter-over-quarter.
- 8 funds opened new Protagonist Therapeutics positions in Q4 2016 and 4 closed out, a net change of +4 holders.
- The largest Protagonist Therapeutics buyer in Q4 2016 was Fidelity Investments, an estimated $8.44M added.
- The largest Protagonist Therapeutics seller in Q4 2016 was BVF Inc, an estimated $7.92M sold.
Based on aggregated 13F filings for Q4 2016.